JUMPSEAT
AEROSPACE NEWS

SK Bioscience Secures UNICEF Procurement Contract

Key Takeaways
  • SK bioscience secures first UNICEF procurement contract.
  • Contract includes supply of influenza vaccines to countries in both hemispheres.
  • Approximately 640,000 doses to be delivered throughout the year.
  • SK bioscience's influenza vaccine, SKYCellflu, received WHO Prequalification certification.
Sign in to view key takeaways Get full access to in-depth analysis and key takeaways.
Sign In
Silver membership required Upgrade to Silver to access Key Takeaways.
Upgrade
Strategic Implications

This contract may indicate SK bioscience's growing presence in global public procurement markets, suggesting a potential expansion of its vaccine supply capabilities. The partnership with UNICEF could strengthen the company's position in the global health landscape, which may lead to increased accessibility of vaccines in countries with limited healthcare resources.

Sign in to view strategic implications Get full access to strategic analysis and expert insights.
Sign In
Silver membership required Upgrade to Silver to access Strategic Implications.
Upgrade

What Happened

Influenza Vaccine Supply Deal Expands Global Public Health Presence

SK bioscience has announced that it has secured its first UNICEF procurement contract, which includes the supply of influenza vaccines to countries in both the Southern and Northern Hemispheres. The company will deliver approximately 640,000 doses throughout the year, with the contract marking a significant milestone in its expansion into the global public procurement market. SK bioscience’s influenza vaccine, SKYCellflu, has received World Health Organization Prequalification certification, demonstrating its strong immunogenicity and safety. This development was first reported by BioSpace.

Source

Advertisement 728 × 90
JUMPSEAT
AEROSPACE NEWS
JUMPSEAT
AEROSPACE NEWS

SK Bioscience Secures UNICEF Procurement Contract

Sponsored by: Jumpseat Solutions
Key Takeaways
  • SK bioscience secures first UNICEF procurement contract.
  • Contract includes supply of influenza vaccines to countries in both hemispheres.
  • Approximately 640,000 doses to be delivered throughout the year.
  • SK bioscience's influenza vaccine, SKYCellflu, received WHO Prequalification certification.
Sign in to view key takeaways Get full access to in-depth analysis and key takeaways.
Sign In
Silver membership required Upgrade to Silver to access Key Takeaways.
Upgrade
Strategic Implications

This contract may indicate SK bioscience's growing presence in global public procurement markets, suggesting a potential expansion of its vaccine supply capabilities. The partnership with UNICEF could strengthen the company's position in the global health landscape, which may lead to increased accessibility of vaccines in countries with limited healthcare resources.

Sign in to view strategic implications Get full access to strategic analysis and expert insights.
Sign In
Silver membership required Upgrade to Silver to access Strategic Implications.
Upgrade

What Happened

Influenza Vaccine Supply Deal Expands Global Public Health Presence

SK bioscience has announced that it has secured its first UNICEF procurement contract, which includes the supply of influenza vaccines to countries in both the Southern and Northern Hemispheres. The company will deliver approximately 640,000 doses throughout the year, with the contract marking a significant milestone in its expansion into the global public procurement market. SK bioscience’s influenza vaccine, SKYCellflu, has received World Health Organization Prequalification certification, demonstrating its strong immunogenicity and safety. This development was first reported by BioSpace.

Source

Advertisement 300 × 250 Google AdSense